Literature DB >> 8105569

Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs.

R D Schulick1, M B Weir, M W Miller, D J Cohen, B L Bermas, G M Shearer.   

Abstract

Three distinct T helper activation pathways contribute to interleukin-2 production by human peripheral blood mononuclear cells following in vitro stimulation with HLA alloantigens in a mixed lymphocyte reaction. These pathways involve both CD4+ and CD8+ T helper cells, as well as self and allogeneic antigen-presenting cells. The pathways are differentially susceptible to cyclosporine in vitro, with the CD4+ T helper cell and selfAPC (CD4 approximately sAPC) pathway being the most sensitive. Furthermore, these pathways are differentially susceptible to immunosuppressive drugs in renal allograft patients, and by functional analysis of these pathways we have identified patients who are at increased risk for rejection of their kidney allografts. The present report provides a longitudinal study of the functional T helper cell status of recently transplanted renal allograft recipients undergoing tapering of their immunosuppressive drugs by testing the ability of recipient PBMC to generate IL-2 in response to pathway-specific stimuli. This study provides evidence that IL-2 generation by T helper pathways is dynamic, fluctuating independently of the commonly followed clinical parameters used to assess graft function and degree of immunosuppression. Significantly, the function of the CD4 approximately sAPC activation pathway correlates with risk of acute rejection. As such, we suggest that periodic assessment of pathway specific T helper function is a more sensitive index for the detection of subtherapeutic dosing of immunosuppressives--and, in particular, for assessing cyclosporine maintenance requirements. Monitoring of pathway specific activity with appropriate cyclosporine dosing adjustments might prevent the initiation of the rejection process and reduce a major source of late graft failure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105569

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation.

Authors:  Hao Zhou; Jian Lin; Shushang Chen; Liqiang Ma; Zhenzhen Qiu; Weidong Chen; Xin'an Zhang; Yi Zhang; Xiuquan Lin
Journal:  Clin Exp Nephrol       Date:  2012-10-06       Impact factor: 2.801

Review 2.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

3.  The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation.

Authors:  N M van Besouw; J M Zuijderwijk; L M B Vaessen; A H M M Balk; A P W M Maat; P H van der Meide; W Weimar
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

4.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  Serial assessment of immune status by circulating CD8 effector T cell frequencies for posttransplant infectious complications.

Authors:  Shinji Uemoto; Kazue Ozawa; Hiroto Egawa; Yasutsugu Takada; Hiroshi Sato; Satoshi Teramukai; Mureo Kasahara; Kohei Ogawa; Masako Ono; Kenji Takai; Masanori Fukushima; Kayo Inaba; Koichi Tanaka
Journal:  Clin Dev Immunol       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.